Velcade+ Doxil: Better than Velcade Alone in Slowing Progression of Multiple Myloma
In a phase II trial led by a University of North Carolina at Chapel Hill School of Medicine researcher found that a newly formulated chemotherapy drug Doxil (doxorubicin delivered via liposomes, or microscopic fat bubbles) combined with standard therapy Velcade slows the progression of multiple myeloma better than Velcade alone.
Multiple myeloma is an advanced cancer of the bone marrow cells.
An interim analysis of study participants who received the combination treatment showed a better response in the combination group than in participants who received standard treatment.
The combination group’s median time to progression - the time interval between the response to treatment and the time the disease starts to show evidence of growing or recurring - was 9.3 months, while those on Velcade alone progressed after 6.5 months.
The study was supported by Johnson & Johnson, which owns Ortho Biotech (has a financial interest in Velcade) the maker of Doxil.
The results were presented by Dr. Robert Orlowski (Lenvel Lee Rothrock associate professor in the department of hematology/oncology at the School of Medicine, and a member of the UNC Lineberger Comprehensive Cancer Center) at the meeting of the American Society of Hematology in Orlando, Florida.
Source: UNC School of Medicine News
Tags: doxil, multiple-myeloma, velcadeRelated Stories
POSTED IN: on anti-cancer ingredients, on blood cancer
0 opinions for Velcade+ Doxil: Better than Velcade Alone in Slowing Progression of Multiple Myloma
No one has left a comment yet. You know what this means, right? You could be first!
Have an opinion? Leave a comment: